Inclusion Criteria:  Diagnosis of nAMD ≥50 years of age at index date Receipt of at least one injection of brolucizumab during the eligibility period Able and willing to provide signed informed consent  Exclusion Criteria:  Received treatment for retinal vein occlusion, diabetic macular edema (DME) and/or myopic choroidal neovascularization (mCNV), and/or has received a new diagnosis of diabetes-related macular degeneration in the index eye within 6 months prior to the index date Receipt of anti-VEGF treatment other than brolucizumab in the index eye at index date Any active intraocular or periocular infection or active intraocular inflammation in the index eye at index date Has been on anti-VEGF treatment for longer than 3 years (before index date) Has a contraindication and is not eligible for treatment with brolucizumab according to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) ("Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)" 2020) Any medical or psychological condition in the treating physician's opinion which may prevent the patient from participating in the study Participating in a parallel interventional clinical study Participating in a parallel non-interventional study (NIS) generating primary data for an anti- VEGF drug.